4 Results for "

water consumption

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "water consumption" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-16688A
CAS No.: 107008-28-6
Target:  

5-HT Receptor

Research Areas:  

Neurological Disease

RU 24969 succinate is a 5-HT receptor agonist with Ki values of 0.38 and 2.5 nM for 5-HT1B and 5-HT1A, respectively. RU 24969 decreases fluid consumption and increases forward locomotion. RU 24969 succinate can be used for the research of neurological disease .
loading...
    loading...
Cat. No.: HY-135057
CAS No.: 4292-10-8
Synonyms: Lauramidopropyl betaine
Research Areas:  

Others

Lauroylamide propylbetaine (35% in water) (Lauramidopropyl betaine) is an ampholytic surfactant for cosmetic and hair compositions to enhance viscosity and has good biodegradability. Lauroylamide propylbetaine (35% in water) promotes CH4 hydrate formation by reducing the induction time and increasing the CH4 consumption rate for hydrate growth .
loading...
    loading...
Cat. No.: HY-P0216A
Target:  

Angiotensin Receptor

Research Areas:  

Cardiovascular Disease

A-779 TFA is a selective angiotensin-(1-7) (Ang-(1-7)) antagonist. A-779 TFA blocks Arachidonic acid release, bradykinin potentiation effects and hypotensive action. A-779 TFA exerts diuretic effects in non-pregnant rats, antidiuretic effects in late-pregnant rats, and also inhibits feed intake and water consumption in late-pregnant rats. A-779 TFA attenuates the regulatory effects of prostacyclin, nitric oxide and thromboxane A2 associated with angiotensin-(1-7). A-779 TFA can be used in studies related to hypertension .
loading...
    loading...
Cat. No.: HY-184378
CAS No.: 2922221-22-3
Research Areas:  

Metabolic Disease Cancer

MDB5 is a Hedgehog pathway and Smoothened inhibitor that binds to the 7-TM domain of Smo . MDB5 reduces hepatic stellate cell activation, extracellular matrix-related gene expression, collagen deposition, hydroxyproline content and epithelial-mesenchymal transition, and prevents sinusoidal endothelial cell capillarization . MDB5 induces G1 and S phase cell cycle arrest, triggers apoptosis by upregulating Bax and downregulating Bcl-2, and also decreases oxygen consumption rate, glucose uptake, transglutaminase activity and fibronectin matrix assembly . MDB5 reduces the levels of liver injury markers, hepatic triglyceride deposition and hepatic steatosis, restores the tissue structure of the kidney and spleen, and inhibits pancreatic tumor growth without causing body weight loss . MDB5 can be loaded into PEG-PCC-g-DC micelles, achieving high drug loading, sustained release, improved water solubility, enhanced cellular uptake and optimized hepatic distribution, with good tolerance in mice . MDB5 is applicable to research related to alcohol-associated liver disease, liver fibrosis and pancreatic cancer .
loading...
    loading...